Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now!
SALE Alopecia Areata Market Report
Alopecia Areata Market Report
Alopecia Areata - Market Insight, Epidemiology And Market Forecast - 2032
  • Published Date : Aug 2023

  • Pages : 200

  • Delivery Time : 24 Hours

  • Region : United States, EU5, Japan

Alopecia Areata Market

  • As per DelveInsight’s analysis, the largest alopecia areata market size was observed the US, approximately 47% which is further expected to increase by 2032.
  • Recently, OLUMIANT was approved by the US FDA for the treatment of alopecia areata. The therapy is expected to generate a decent alopecia areata market share of approximately 300 million by 2032.
  • A complicated, polygenic, autoimmune condition called alopecia areata causes non-scarring alopecia patches on the scalp and body hair, which can be emotionally distressing. Clinically diverse, alopecia areata has an erratic course, with 80% of patients seeing spontaneous hair growth within the first year and the possibility of rapid recurrence at any time. Instances that start in childhood are more severe than instances that start as adults.
  • Usually, the pattern of hair loss and the patient's medical history can be used to diagnose alopecia areata. To confirm the diagnosis, a biopsy may be required in some circumstances. Dermoscopy (trichoscopy) has recently become a useful auxiliary tool. Dermoscopic observations that indicate early regrowth include yellow and black spots, broken hairs, exclamation point hairs, and short vellus hairs.
  • Topical, locally injected, or systemic steroids, contact immunotherapy, topical minoxidil, topical irritants like anthralin, and systemic immunosuppressants like cyclosporine or methotrexate are among the treatments for alopecia areata. JAK inhibitors, platelet-rich plasma, recombinant IL-2, hydroxychloroquine, simvastatin with ezetimibe, and excimer laser are examples of current and effective experimental therapies.
  • As per Alopecia Areata Consensus of Experts (ACE) Study, when full regrowth has been attained and maintained for six months, or when regrowth is adequate to be controlled topically, systemic therapy should be stopped.
  • OLUMIANT being the only approved therapy leaves patients with limited options for the management of their condition. When taken in dermatology, rheumatology, or gastroenterology, JAK inhibitors—promising therapy alternatives for alopecia areata—are listed by the US FDA's "black box warning" for an elevated risk of severe infection, mortality, malignancy, and significant CVS events.
  • The emerging alopecia areata therapies in the market for include Concert Pharmaceuticals’ (CTP-543), Pfizer’s (PF-06651600), Legacy Healthcare’s (LH 8) and others have the potential to create a significant positive shift in the market size.
  • Considering the current alopecia areata treatment landscape, minoxidil is widely used among the patients of alopecia areata but a high relapse rate is observed that needs to be addressed and shape the future alopecia areata market.

DelveInsight’s “Alopecia Areata Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of historical and forecasted epidemiology as well as market trends of in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. The report also provides in-depth analysis of alopecia areata, current diagnostic algorithms and unmet medical needs and SWOT analysis emerging drugs, market share of individual therapies, current and forecasted 7MM market size to better analyze and visualize the market and curate the best opportunities and assess the market’s potential.

Alopecia Areata report highlights the major types of alopecia areata observed in different population and the preferred therapeutic approaches. It also provides in depth analysis of market including the recently approved OLUMIANT and off label therapies (corticosteroids, minoxidil, etc.) for the management.

Report Metrics

Details

Study Period

2019 to 2032

Forecast Period

2023 to 2032

Geographies Covered

The US, EU4 (Germany, France, Italy, and Spain) and UK, and Japan

Alopecia Areata Epidemiology

  • Type
  • Age of Onset
  • Severity
  • Comorbidities

Alopecia Areata Market

  • Region
  • Therapies

Alopecia Areata Market Size

Request Sample PDF to Know

Alopecia Areata Market Analysis
  • KOL Views
  • SWOT Analysis
  • Unmet Needs
Alopecia Areata Companies

IConcert Pharmaceuticals, Pfizer, Legacy Healthcare, Regeneron Pharmaceuticals, Sanofi. AnaptysBio, Horizon Therapeutics, Bristol Myers Squibb, Zelgen Biopharmaceuticals, Suzhou, Reistone Biopharma and others

Alopecia Areata Market Analysis

  • Key players such as Concert Pharmaceuticals’ (CTP-543), Pfizer’s’ (PF-06651600), Legacy HealthCare’s’ (LH 8) and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of alopecia areata.
  • In 2022, the US captured the highest Alopecia Areata market share (64%) out of all the 7MM countries.
  • EU4 and the UK accounted for nearly (21%) Alopecia Areata market share, and Germany accounted for the highest share in Europe in 2022.
  • Japan accounted for approximately 15% of the Alopecia Areata market share. It is expected to increase at a CAGR of ~18% during the forecast period (2023–2032).

Market Share

2022

CAGR

United States

64%

~29%

EU4 and the UK

21%

~21%

Japan

15%

~18%

Alopecia Areata Drug Chapters

The alopecia areata market report's drugs chapter includes an in depth assessment of both late-stage (Phase III and Phase II) pipeline therapeutics as well as treatments that have been marketed for the treatment. Alopecia areata expressive pharmacological action, agreements and collaborations, approval and patent information, benefits and drawbacks of each featured therapy, and the most recent news and press releases are also included.

Additionally, the information related to the safety and efficacy is also highlighted based on which OLUMIANT is approved. Also, the pivotal trials are mentioned based on which the companies (Concert Pharmaceuticals, Pfizer, Legacy Healthcare and others) are seeking approvals.

Marketed Alopecia Areata Drugs

OLUMIANT (baricitinib): Eli Lilly and Company/Incyte Corporation

OLUMIANT is a Janus kinase (JAK) inhibitor which blocks the activity of one or more of a specific family of enzymes, interfering with the pathway that leads to inflammation. The results of clinical study demonstrated the efficacy of OLUMIANT in the alopecia areata patients. Moreover, there has been a significant unmet medical need for people with alopecia areata until the approval of OLUMIANT.

The drug is already approved in multiple indications like atopic dermatitis and rheumatoid arthritis, but the drug is also associated with severe adverse events. Hence, OLUMIANT carries a black box warning regarding serious infections, malignancy, and mortality.

Emerging Alopecia Areata Drugs

CTP-543 (deuruxolitinib): Concert Pharmaceuticals

Concert Pharmaceuticals’ CTP-543 is an oral inhibitor of JAK1 and JAK2 designed to target the immunological basis of alopecia areata. The drug received breakthrough designation and orphan designation from the US FDA for the treatment of alopecia areata. The company reported positive results from late phase clinical studies demonstrating its efficacy in the patients.

When compared with Pfizer’s PF-06651600, Concerts’ CTP-543 demonstrated nearly 10% better primary endpoint of SALT score <20. Hence, the drug can prove itself an asset for the company and target the unmet needs of the patients.

PF-06651600 (ritlecitinib): Pfizer

PF-06651600 is a dual inhibitor of the TEC family of tyrosine kinases and JAK3, is an investigational oral once-daily treatment, i.e., the first in a new class of oral highly selective kinase inhibitors. Currently, the company is in preregistration phase for the treatment of alopecia areata.

The drug is expected to enter the alopecia areata market ahead of other therapies. Moreover with least side effects and a better dosing frequency of once daily, it can offer a better compliance over other therapies, and can attain a decent market share.

Drug

Company

MoA

RoA

Class

CTP-543

Concert Pharmaceuticals

Janus kinase 1 inhibitors

Oral

Small Molecules

PF-06651600

Pfizer

Emt protein-tyrosine kinase inhibitors

Oral

Small Molecules

LH 8

Legacy Healthcare

Undefined

Topical

New botanical entity

Alopecia Areata Market Outlook

Alopecia areata is the second most common form after androgenetic alopecia. It often appears during childhood and can be different for everyone. Therapy efficacy is difficult to estimate due to the unpredictable course of the disease, and spontaneous remission is often observed within the first year. The current therapies focus on immunosuppression that does not influence the long-term course of the disease, creating an unmet need for novel therapies. Alopecia areata treatment involves corticosteroids, topical sensitization therapy, topical irritation therapy, and others. Topical corticosteroids possess fewer side effects and are widely used as a first-line treatment for alopecia areata.

Other therapies involved in the treatment of alopecia areata are methotrexate in combination with oral corticosteroids is more effective; cyclosporine A monotherapy or combined with oral corticosteroids has a moderate effect in severe alopecia areata. Furthermore, topical minoxidil and tacrolimus are frequently used for the patchy alopecia areata and on the eyebrows.

The market presents a wide opportunity for these players to capitalize on the untapped market. However, continuous efforts are further needed to develop drugs treating alopecia areata. As the entire landscape consists of only a single approved drug and off-label therapies, any significant development in this direction is expected to create a tectonic impact on the existing market scenario during the forecast period (2023–2032).

Alopecia Areata Drug Class Insights

For the treatment of alopecia areata, corticosteroids are considered as the first line treatment for the patients due to low side effects associated. They are available in broad spectrum such as solutions, shampoos, foams etc.

Intralesional injection of corticosteroids are recommended for the patchy alopecia, combined with topical corticosteroids.

Systemic corticosteroids have been used in the treatment of alopecia areata as oral pulse therapy (PT), intravenous (IV) PT, intramuscularly (IM), or continuously (CT). Oral corticosteroids are considered an appropriate first-line treatment for moderate to severe alopecia areata in adults (SALT > 30%), alone or combined with topical corticosteroids.

In daily practice, minoxidil is frequently used to manage patchy alopecia areata. However, it should be noted that topical minoxidil has no anti-inflammatory effect. It is mainly used to enhance hair growth as a co-medication with other treatments which can stop or reverse the inflammatory infiltrate.

Alopecia Areata Drugs Uptake

This section focuses on the uptake rate of potential alopecia areata drugs expected to be launched in the market during 2019–2032. For instance, for PF-06651600 which is expected to be launched in the US in 2023, the drug uptake is expected to be medium, with a probability-adjusted peak patient share of ~10% in the US, expected to peak at 9 years from the year of launch.

Further detailed analysis of emerging therapies drug uptake in the report…

Alopecia Areata Epidemiology

As the market is derived using a patient-based model, the alopecia areata epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Alopecia Areata, Total Diagnosed Cases of Alopecia Areata, Type-Specific Cases of Alopecia Areata, Cases of Alopecia Areata Based on Age of Onset, Severity-Specific Cases of Alopecia Areata, and Comorbidities Associated With Alopecia Areata in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

  • In 2022, the total prevalent cases of alopecia areata in the United States were approximately 704,000 cases which is projected to increase during the forecast period (2023–2032).
  • The total prevalent cases of alopecia areata in EU4 and the UK were approximately 447,000 in 2022. The cases are projected to increase during the forecast period (2023–2032).
  • The total prevalent population of alopecia areata in Japan were approximately 334,000 cases in 2022.
  • In 2022, for severity specific cases, ~10% of the patient share were estimated for the mild, ~60% moderate, and ~30% cases for severe in the US.

Alopecia Areata Pipeline Development Activities

The alopecia areata market report provides insights into different therapeutic candidates in late as well as early stage (Phase III, Phase II, and Phase I) of development. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The alopecia areata market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for alopecia areata emerging therapies. The reports covers the assets with advancements in drug delivery systems and targeted approaches aid in discovering novel therapeutics that promise better medication for alopecia areata in the future

Alopecia Areata Disease Understanding and Treatment

Alopecia Areata Overview

People of all ages, both sexes, and all ethnic groups can develop alopecia areata, a common autoimmune skin condition that causes hair loss on the scalp, face, and occasionally other regions of the body.

Over time, there has been significant drift in the etiology of alopecia areata, and several research have proposed various etiologies for the disorder. Most alopecia areata research makes a compelling argument for the involvement of genetic, autoimmune, and environmental variables in the etiology.

Alopecia Areata Diagnosis

An extensive medical and family history should be obtained from an alopecia areata patient, and their entire body, including their nails, should be thoroughly examined. A hair pull test and dermatoscopy should always be added to this. Additional tests, such as a scalp biopsy, a fungal culture, or serology for other autoimmune illnesses or infectious diseases (like syphilis), may be required when clinical findings do not allow for a certain diagnosis.

Further details related to country-based variations are provided in the report…

Alopecia Areata Treatment

With largely unsatisfactory results and significant recurrence rates, particularly in more severe instances, current medications for alopecia areata attempt to immunosuppress or immunomodulate the activity of the illness. Due to its modest side-effect profile when administered carefully, topical corticosteroids are frequently utilized in the treatment of restricted patchy alopecia areata and as first-line therapy for children. In more severe instances, they are also suggested as an adjuvant treatment. First-line recommendations for treating limited patchy alopecia areata include intralesional injections of corticosteroids, either alone or in combination with topical corticosteroids. Alopecia areata has been treated with systemic corticosteroids administered orally, intravenously, intramuscularly, or continuously (CT). In everyday practice, patchy alopecia areata is usually treated with minoxidil.

The treatment landscape of alopecia areata is expected to change substantially and experience growth. The upcoming launch of innovative therapies such as CTP-543 (Concert Pharmaceuticals), PF-06651600 (Pfizer), LH 8 (Legacy Healthcare) and others are expected to drive the market further.

KOL Views

To keep up with current market trends, we take KOLs and ’SME’s opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on alopecia areata evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, and drug uptake, along with challenges related to accessibility, include Medical/scientific writers and Professors from renowned universities in the US, Europe, the UK, and Japan.

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Dermatology and Laser Center, Yale University School of Medicine, University of Sheffield etc., were contacted. Their opinion helped understand and validate current and emerging therapy treatment patterns of alopecia areata market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

As per the expert opinion “Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia areata. So, in my opinion the approval of OLUMIANT will help to fulfill a significant unmet need for patients with severe alopecia areata.”

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging alopecia areata therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in trials for alopecia areata, one of the most important primary endpoints is percentage of patients achieving an absolute severity of alopecia tool, and relative change in SALT scores from baseline. Based on these, the overall efficacy is evaluated.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging alopecia areata therapies are decided.

Alopecia Areata Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine in comparison to the benefit it provides to patients who are being treated sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect alopecia areata market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Patient Access Program For OLUMIANT

Olumiant together program

Patient access program OLUMIANT together program offers multiple resources to patients, including insurance and reimbursement support. It also confirms the insurance coverage, assists with enrollment in the savings program and explores savings options if commercially insured.

Scope of Alopecia Areata Market Report

  • The alopecia areata market report includes a section on key events, an executive summary, and a comprehensive overview of alopecia areata, outlining its diagnosis, types, risk factors, pathophysiology, and treatment guidelines, market outlook.
  • The epidemiological segments and forecast, as well as the future growth potential of diagnostic rate, illness progression, and therapy recommendations, have all been covered in detail.
  • Current alopecia areata market and emerging therapies are covered, description regarding their stages, and their impact on the current treatment landscape is covered
  • The alopecia areata market report also covers a thorough analysis of the alopecia areata market, historical and projected alopecia areata market size, market share by therapy, in-depth assumptions, and rationale behind our approach.

Key Questions

Alopecia Areata Market Insights

  • What were the were the overall alopecia areata market sizes, by therapy, in terms of market share (%) in 2019, and what would they be in 2032? What are the underlying causes of this expansion?
  • What kind of the uptake the new therapies are going to witness in coming years in alopecia areata patients?
  • Being the only approved therapy, will OLUMIANT emerge as largest revenue generating therapy?
  • Which therapy is going to be the major revenue generating by 2032?
  • What are the differences in price between regions for the alopecia areata treatments?
  • How will alopecia areata market dynamics and associated trends be impacted by market drivers, obstacles, and potential future opportunities?

Alopecia Areata Epidemiology Insights

  • What diseases, costs, and unmet needs are associated with alopecia areata? What will the patient population for alopecia areata patients' growth possibilities be across the 7MM?
  • What is the historical and projected patient population for alopecia areata in the US, the EU4 (Germany, France, Italy, Spain), the UK, and Japan?
  • What factors will have an impact on the rise in alopecia areata diagnoses?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

  • What alternatives are there for treating alopecia areata? What are the recommended treatments for alopecia areata in the US, Europe, the UK, and Japan right now?
  • How many alopecia areata companies are working to treat alopecia areata?
  • What novel therapies, targets, mechanisms of action, and technologies have recently been created to get around the shortcomings of present alopecia areata therapies?
  • What financial burden do approved alopecia areata therapies place on the patient?
  • What are the problems with pricing, recently approved alopecia areata therapies' accessibility that vary by nation?

1. Key Insights

2. Report Introduction

3. Alopecia areata Market Overview at a Glance

3.1. Market Share (%) Distribution of alopecia areata in 2019

3.2. Market Share (%) Distribution of alopecia areata in 2032

4. Executive Summary of Alopecia areata

5. Key Events

6. Disease Background and Overview

6.1. Introduction

6.2. Clinical Manifestation

6.3. Risk Factors

6.4. Prognosis

6.5. Diagnosis

6.5.1. Differential diagnosis

6.5.2. Comorbidities associated with alopecia areata

6.6. Treatment

6.6.1. Treatment guidelines

6.6.2. The Alopecia Areata Consensus of Experts (ACE) Study

6.6.3. Other guidelines

7. Alopecia areata Methodology

8. Alopecia areata Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale

8.3. Total Prevalent Cases of Alopecia Areata in the 7MM

8.4. Total Diagnosed Cases of Alopecia Areata in the 7MM

8.5. The United States

8.5.1. Total prevalent cases of alopecia areata in the US

8.5.2. Total diagnosed cases of alopecia areata in the US

8.5.3. Type-specific cases of alopecia areata in the US

8.5.4. Cases of alopecia areata based on age of onset in the US

8.5.5. Severity-specific cases of alopecia areata in the US

8.5.6. Comorbidities associated with alopecia areata in the US

8.6. EU4 and the UK

8.6.1. Total prevalent cases of alopecia areata in EU4 and the UK

8.6.2. Total diagnosed cases of alopecia areata in EU4 and the UK

8.6.3. Type-specific cases of alopecia areata in EU4 and the UK

8.6.4. Cases of alopecia areata based on age of onset in EU4 and the UK

8.6.5. Severity-specific cases of alopecia areata in EU4 and the UK

8.6.6. Comorbidities associated with alopecia areata in EU4 and the UK

8.7. Japan

8.7.1. Total prevalent cases of alopecia areata in Japan

8.7.2. Total diagnosed cases of alopecia areata in Japan

8.7.3. Type-specific cases of alopecia areata in Japan

8.7.4. Cases of alopecia areata based on age of onset in Japan

8.7.5. Severity-specific cases of alopecia areata in Japan

8.7.6. Comorbidities associated with alopecia areata in Japan

9. Alopecia areata Patient Journey

10. Marketed Alopecia areata Therapies

10.1. OLUMIANT (baricitinib): Eli Lilly and Company/Incyte Corporation

10.1.1. Drug description

10.1.2. Regulatory milestone

10.1.3. Other development activities

10.1.4. Clinical development

10.1.5. Ongoing pipeline activities

11. Emerging Alopecia areata Therapies

11.1. Key Cross of emerging therapies

11.2. CTP-543 (deuruxolitinib): Concert Pharmaceuticals

11.2.1. Drug description

11.2.2. Other development activities

11.2.3. Clinical development

11.2.3.1. Clinical trials information

11.2.4. Safety and efficacy

11.3. PF-06651600 (ritlecitinib): Pfizer

11.3.1. Drug description

11.3.2. Other development activities

11.3.3. Clinical development

11.3.3.1. Clinical trials information

11.3.4. Safety and efficacy

11.4. Coacillium (LH-8): Legacy Healthcare

11.4.1. Drug description

11.4.2. Clinical development

11.4.2.1. Clinical trials information

11.4.3. Safety and efficacy

11.5. DUPIXENT (dupilumab): Regeneron Pharmaceuticals/Sanofi

11.5.1. Drug description

11.5.2. Other development activities

11.5.3. Clinical development

11.5.3.1. Clinical trials information

11.5.4. Safety and efficacy

11.6. Etrasimod: Pfizer

11.6.1. Drug description

11.6.2. Other development activities

11.6.3. Clinical development

11.6.3.1. Clinical trials information

11.7. Rosnilimab: AnaptysBio

11.7.1. Drug description

11.7.2. Other development activities

11.7.3. Clinical development

11.7.3.1. Clinical trials information

11.7.4. Safety and efficacy

11.8. HZN-7734 (daxdilimab): Horizon Therapeutics

11.8.1. Drug description

11.8.2. Clinical development

11.8.2.1. Clinical trials information

11.9. SOTYKTU (deucravacitinib): Bristol Myers Squibb

11.9.1. Drug description

11.9.2. Clinical development

11.9.2.1. Clinical trials information

11.10. ORENCIA (abatacept): Bristol Myers Squibb (BMS)

11.10.1. Drug description

11.10.2. Other development activities

11.10.3. Clinical development

11.10.3.1. Clinical trials information

11.10.4. Safety and efficacy

11.11. Jaktinib: Suzhou Zelgen Biopharmaceuticals

11.11.1. Drug description

11.11.2. Clinical development

11.11.2.1. Clinical trials information

11.12. SHR0302 (ivarmacitinib): Reistone Biopharma

11.12.1. Drug description

11.12.2. Other development activities

11.12.3. Clinical development

11.12.3.1. Clinical trials information

11.12.4. Safety and efficacy

12. Alopecia areata: 7 Major Market Analysis

12.1. Key Findings

12.2. Alopecia areata Market Outlook

12.3. Attribute Analysis

12.4. Key Market Forecast Assumption

12.5. Total Market Size of Alopecia Areata in the 7MM

12.6. United States Alopecia areata Market Size

12.6.1. Total market size of alopecia areata in the US

12.6.2. Market size of alopecia areata by therapies in the US

12.7. EU4 and the UK Alopecia areata Market

12.7.1. Total market size of alopecia areata in EU4 and the UK

12.7.2. Market size of alopecia areata by therapies in EU4 and the UK

12.8. Japan Alopecia areata Market

12.8.1. Total market size of alopecia areata in Japan

12.8.2. Market size of alopecia areata by therapies in Japan

13. Alopecia areata SWOT Analysis

14. Alopecia areata Unmet Needs

15. Alopecia areata KOL Views

16. Alopecia areata Market Access and Reimbursement

16.1. The United States

16.1.1. Centre for Medicare & Medicaid Services (CMS)

16.1.2. Patient access program and copay

16.2. EU4 and the UK

16.2.1. Germany

16.2.2. France

16.2.3. Italy

16.2.4. Spain

16.2.5. United Kingdom

16.3. Japan

16.3.1. MHLW

17. Appendix

17.1. Bibliography

17.2. Acronyms and Abbreviations

17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables:

    Table 1: Summary of Alopecia Areata: Epidemiology and Market Size (2019–2032)

    Table 2: Key Events

    Table 3: Clinical Manifestations of Alopecia Areata Variants

    Table 4: Gene Variants Associated with Alopecia Areata

    Table 5: Characteristic Dermatoscopic Findings in Alopecia Areata

    Table 6: Differential Diagnosis of Patchy and Diffuse Alopecia Areata Grouped by Children/Adolescents and Adults

    Table 7: Common Comorbidities in Alopecia Areata

    Table 8: ACE Consensus for Topical Treatments in Alopecia Areata

    Table 9: ACE Consensus for Appropriate First-Line Treatment (s) in Specific Patient Age Groups

    Table 10: Summary of Recommended Therapeutic Modalities in Guidelines or Expert Consensus Reports

    Table 11: Total Prevalent Cases of Alopecia Areata in 7MM (2019–2032)

    Table 12: Total Diagnosed Cases of Alopecia Areata in 7MM (2019–2032)

    Table 13: Total Prevalent Cases of Alopecia Areata in the US (2019–2032)

    Table 14: Total Diagnosed Cases of Alopecia Areata in the United States (2019–2032)

    Table 15: Type-specific Cases of Alopecia Areata in the US (2019–2032)

    Table 16: Cases of Alopecia Areata Based on Age of Onset in the US (2019–2032)

    Table 17: Severity-specific Cases of Alopecia Areata in the US (2019–2032)

    Table 18: Comorbidities associated with alopecia areata in the US (2019–2032)

    Table 19: Total Prevalent Cases of Alopecia areata in EU4 and the UK (2019–2032)

    Table 20: Total Diagnosed Cases of Alopecia Areata in EU4 and the UK (2019–2032)

    Table 21: Type-specific Cases of Alopecia Areata in EU4 and the UK (2019–2032)

    Table 22: Cases of Alopecia Areata Based on Age of Onset in EU4 and the UK (2019–2032)

    Table 23: Severity-specific Cases of Alopecia Areata in EU4 and the UK (2019–2032)

    Table 24: Comorbidities associated with alopecia areata in EU4 and the UK (2019–2032)

    Table 25: Total Prevalent Cases of Alopecia Areata in Japan (2019–2032)

    Table 26: Total Diagnosed Cases of Alopecia Areata in Japan (2019–2032)

    Table 27: Type-specific Cases of Alopecia Areata in Japan (2019–2032)

    Table 28: Cases of Alopecia Areata Based on Age of Onset in Japan (2019–2032)

    Table 29: Severity-specific Cases of Alopecia Areata in Japan (2019–2032)

    Table 30: Comorbidities associated with alopecia areata in Japan (2019–2032)

    Table 31: Key Cross of Emerging Drugs

    Table 32: Key Cross of Emerging Drugs

    Table 33: Key Cross of Emerging Drugs

    Table 34: CTP-543 (deuruxolitinib), Clinical Trial Description, 2023

    Table 35: PF-06651600 (ritlecitinib), Clinical Trial Description, 2023

    Table 36: Coacillium (LH-8), Clinical Trial Description, 2023

    Table 37: DUPIXENT (dupilumab), Clinical Trial Description, 2023

    Table 38: Etrasimod, Clinical Trial Description, 2023

    Table 39: Rosnilimab, Clinical Trial Description, 2023

    Table 40: HZN-7734 (daxdilimab), Clinical Trial Description, 2023

    Table 41: SOTYKTU (Deucravacitinib), Clinical Trial Description, 2023

    Table 42: ORENCIA (abatacept), Clinical Trial Description, 2023

    Table 43: Jaktinib, Clinical Trial Description, 2023

    Table 44: SHR0302 (ivarmacitinib), Clinical Trial Description, 2023

    Table 45: Total Market Size of Alopecia Areata in the 7MM, in USD million (2019–2032)

    Table 46: Market Size of Alopecia Areata in the US, in USD million (2019–2032)

    Table 47: Market Size of Alopecia Areata in the US by Therapies, in USD million (2019–2032)

    Table 48: Market Size of Alopecia Areata in EU4 and the UK, in USD million (2019–2032)

    Table 49: Market Size of Alopecia Areata by Therapies in EU4 and the UK, in USD million (2019–2032)

    Table 50: Market Size of Alopecia Areata in Japan, in USD million (2019–2032)

    Table 51:Market Size of Alopecia Areata by Therapies in Japan, in USD million (2019–2032)

    Table 52: Weighted Score Based on Ranking

    Table 53: Key Market Forecast Assumptions for CTP-543

    Table 54: Key Market Forecast Assumptions for PF-06651600

    Table 55: Key Market Forecast Assumptions for LH-8

List of Figures:

    Figure 1: Clinical Variants of Alopecia Areata

    Figure 2: Less Common Clinical Variants of Alopecia Areata

    Figure 3: Nail Abnormalities Associated with Alopecia Areata

    Figure 4: Risk Factors for Alopecia Areata

    Figure 5: Histopathologic Features of Alopecia Areata

    Figure 6: Treatment of Alopecia Areata

    Figure 7: Total Prevalent Cases of Alopecia Areata in the 7MM (2019–2032)

    Figure 8: Total Diagnosed Cases of Alopecia Areata in the 7MM (2019–2032)

    Figure 9: Total Prevalent Cases of Alopecia Areata in the US (2019–2032)

    Figure 10: Total Diagnosed Cases of Alopecia Areata in the US (2019–2032)

    Figure 11: Type-specific Cases of Alopecia Areata in the US (2019–2032)

    Figure 12: Cases of Alopecia Areata Based on Age of Onset in the US (2019–2032)

    Figure 13: Severity-specific Cases of Alopecia Areata in the US (2019–2032)

    Figure 14: Comorbidities associated with alopecia areata in the US (2019–2032)

    Figure 15: Total Prevalent Cases of Alopecia Areata in EU4 and the UK (2019–2032)

    Figure 16: Total Diagnosed Cases of Alopecia Areata in EU4 and the UK (2019–2032)

    Figure 17: Type-specific Cases of Alopecia Areata in EU4 and the UK (2019–2032)

    Figure 18: Cases of Alopecia Areata Based on Age of Onset in EU4 and the UK (2019–2032)

    Figure 19: Severity-specific Cases of Alopecia Areata in EU4 and the UK (2019–2032)

    Figure 20: Comorbidities associated with alopecia areata in EU4 and the UK (2019–2032)

    Figure 21: Total Prevalent Cases of Alopecia Areata in Japan (2019–2032)

    Figure 22: Total Diagnosed Cases of Alopecia Areata in Japan (2019–2032)

    Figure 23: Type-specific Cases of Alopecia Areata in Japan (2019–2032)

    Figure 24: Cases of Alopecia Areata Based on Age of Onset in Japan (2019–2032)

    Figure 25: Severity-specific Cases of Alopecia Areata in Japan (2019–2032)

    Figure 26: Comorbidities associated with alopecia areata in Japan (2019–2032)

    Figure 27: Total Market Size of Alopecia Areata in the 7MM (2019–2032)

    Figure 28: Market Size of Alopecia Areata in the US (2019–2032)

    Figure 29: Market Size of Alopecia Areata by Therapies in the US (2019–2032)

    Figure 30: Market Size of Alopecia Areata in EU4 and the UK (2019–2032)

    Figure 31: Market Size of Alopecia Areata by Therapies in EU4 and the UK (2019–2032)

    Figure 32: Market Size of Alopecia Areata in Japan (2019–2032)

    Figure 33:Market Size of Alopecia Areata by Therapies in Japan (2019–2032)

    Figure 34: Health Technology Assessment

    Figure 35: Reimbursement Process in Germany

    Figure 36: Reimbursement Process in France

    Figure 37: Reimbursement Process in Italy

    Figure 38: Reimbursement Process in Spain

    Figure 39: Reimbursement Process in the United Kingdom

    Figure 40: Reimbursement Process in Japan

List of Companies:

    Concert Pharmaceuticals

    Pfizer

    Legacy Healthcare

    Regeneron Pharmaceuticals

    Sanofi

    AnaptysBio

    Horizon Therapeutics

    Bristol Myers Squibb

    Zelgen Biopharmaceuticals

    Suzhou

    Reistone Biopharma

Alopecia Areata Market

Related Reports

Alopecia Areata - Pipeline Insight, 2023

Alopecia Areata - Pipeline Insight, 2023

Alopecia Areata - Epidemiology Forecast - 2032

Alopecia Areata - Epidemiology Forecast - 2032

Tags:

loader

Request Sample

View Pricing